Sector News

AstraZeneca, betting on biologics, will build a $285M facility in Sweden

May 18, 2015
Life sciences
AstraZeneca CEO Pascal Soriot is counting on the company’s cancer drug pipeline to help it climb out of the revenue hole it has fallen into, and he figures his company needs more manufacturing capacity for the coming launches. Toward that end, the U.K. drugmaker says it will build a $285 million biologics manufacturing facility in Sweden and add up to 250 jobs.
 
The new filling and packaging facility for protein-based drugs will be at its Södertälje site, home of its largest tablets and capsules manufacturing operation. It expects to be producing product for clinical trials by 2018 for programs for both AstraZeneca and its MedImmune biotech division and be ready for commercial production the next year. When fully operational, it will add 150 to 250 jobs, AstraZeneca said in an announcement today.
 
“This is a strategically important investment for AstraZeneca to support the accelerating development of biotech medicines, which now make up around half of our pipeline,” Soriot said today in a statement. “We expect to bring a significantly increased number of new specialty care medicines to patients in the coming years, driven in large part by biologics. This new plant will give us greater capacity and flexibility to handle clinical trials, and will also play an important role in our future commercial production.”
 
The announcement comes after AstraZeneca laid out plans last fall to spend more than $200 million to expand a biologics facility in Frederick, MD. It said the Sweden project is one piece of a “three-part program to expand AstraZeneca’s biologics manufacturing capabilities,” details of which will be provided in “coming years.”
 
Like other drugmakers, AstraZeneca is turning more to large-molecule, large-profit specialty drugs to drive its future. Hammered by generic competition for blockbuster acid reflux drug Nexium, AstraZeneca saw revenue fall 6% in the last quarter to $6.06 billion.
 
One area the drugmaker is looking to is anti-PD-L1 immuno-oncology drugs, a hot new field that is expected to generate lots of money for successful products. But AstraZeneca recently sold off some of the upside potential for its PD-L1 blood cancer candidate with a $450 million deal for Celgene to help develop and market it. On the flip side, it’s paying Innate Pharma $250 million to strengthen its immuno-oncology capabilities. AstraZeneca is trailing some other competitors in the field, like Bristol-Myers Squibb, whose Opdivo is approved and forging quickly ahead.
 
By Eric Palmer
 

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

November 22, 2020

Belgium is ‘European biotech leader’ for 3rd year in a row

Life sciences

Belgian companies account for just under a quarter (24%) of the total stock market value of all public biotech companies in Europe.

November 22, 2020

J&J, following BMS, pledges $100M to address racism and health inequities

Life sciences

Johnson & Johnson is re-upping its commitment to addressing health inequities as the pandemic lays bare long-standing divisions.

November 22, 2020

Sanofi sponsors Parkinson’s Foundation’s genetic study with $1M for free testing

Life sciences

It’s estimated that 10% to 15% of people with Parkinson’s have a genetic form of the disease and Sanofi Genzyme is backing a new study to help find those people.

Send this to a friend